Product Description:

• TECFIDERA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

How to use:

• Starting dose: 120 mg twice a day, orally, for 7 days
• Maintenance dose after 7 days: 240 mg twice a day, orally
• Swallow TECFIDERA capsules whole and intact. Do not crush, chew, or sprinkle capsule contents on food

Caution & Warnings:

• Anaphylaxis and angioedema: Discontinue and do not restart TECFIDERA if these occur.
• Progressive multifocal leukoencephalopathy (PML): Withhold TECFIDERA at the first sign or symptom suggestive of PML.
• Herpes zoster and other serious opportunistic infections: Consider withholding TECFIDERA in cases of serious infection until the infection has resolved.
• Lymphopenia: Obtain a CBC including lymphocyte count before initiating TECFIDERA, after 6 months, and every 6 to 12 months thereafter. Consider interruption of TECFIDERA if lymphocyte counts <0.5 x 109/L persist for more than six months.
• Liver injury: Obtain serum aminotransferase, alkaline phosphatase, and total bilirubin levels before initiating TECFIDERA and during treatment, as clinically indicated. Discontinue TECFIDERA if clinically significant liver injury induced by TECFIDERA is suspected.

Ingredients:

• Dimethyl fumarate 120Mg.